These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38007223)

  • 1. Interval colorectal cancers after negative faecal immunochemical test in the New Zealand Bowel Screening Pilot.
    Saw KS; Sexton K; Frankish P; Hulme-Moir M; Bissett I; Parry S
    BMJ Open Gastroenterol; 2023 Nov; 10(1):. PubMed ID: 38007223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval cancers in a national colorectal screening programme based on faecal immunochemical testing: Implications for faecal haemoglobin concentration threshold and sex inequality.
    Clark GR; Godfrey T; Purdie C; Strachan J; Carey FA; Fraser CG; Steele RJ
    J Med Screen; 2024 Mar; 31(1):21-27. PubMed ID: 37469171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-risk symptoms and quantitative faecal immunochemical test accuracy: Systematic review and meta-analysis.
    Pin Vieito N; Zarraquiños S; Cubiella J
    World J Gastroenterol; 2019 May; 25(19):2383-2401. PubMed ID: 31148909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.
    Tran TN; Peeters M; Hoeck S; Van Hal G; Janssens S; De Schutter H
    Br J Cancer; 2022 Apr; 126(7):1091-1099. PubMed ID: 35022524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do faecal test-based colorectal cancer screening pilots provide data that are reflected in subsequent programmes? Evidence from interval cancer proportions.
    Clark GR; Steele RJ; Fraser CG
    Ann Clin Biochem; 2022 Nov; 59(6):450-452. PubMed ID: 36031942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment.
    Ribe SG; Botteri E; Løberg M; Randel KR; Kalager M; Nilsen JA; Gulichsen EH; Holme Ø
    Int J Cancer; 2023 Apr; 152(7):1414-1424. PubMed ID: 36346118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One or two faecal immunochemical tests in an organised population-based colorectal cancer screening programme in Murcia (Spain).
    Tourne-Garcia C; Perez-Riquelme F; Monteagudo-Piqueras O; Fraser CG; Yepes-Garcia P
    J Med Screen; 2022 Dec; 29(4):231-240. PubMed ID: 35578555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal diagnostic accuracy of quantitative faecal immunochemical test positivity thresholds for colorectal cancer detection in primary health care: A community-based cohort study.
    Pin-Vieito N; García Nimo L; Bujanda L; Román Alonso B; Gutierrez-Stampa MÁ; Aguilar-Gama V; Portillo I; Cubiella J
    United European Gastroenterol J; 2021 Mar; 9(2):256-267. PubMed ID: 32778002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy.
    Senore C; Zappa M; Campari C; Crotta S; Armaroli P; Arrigoni A; Cassoni P; Colla R; Fracchia M; Gili F; Grazzini G; Lolli R; Menozzi P; Orione L; Polizzi S; Rapi S; Riggi E; Rubeca T; Sassatelli R; Visioli C; Segnan N
    Gut; 2020 Mar; 69(3):523-530. PubMed ID: 31455608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
    Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
    United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round.
    Digby J; Fraser CG; Carey FA; Diament RH; Balsitis M; Steele RJ
    J Med Screen; 2017 Jun; 24(2):62-68. PubMed ID: 27370211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison with first round findings of faecal haemoglobin concentrations and clinical outcomes in the second round of a biennial faecal immunochemical test based colorectal cancer screening programme.
    Clark GR; Fraser CG; Strachan JA; Steele RJ
    J Med Screen; 2022 Dec; 29(4):249-254. PubMed ID: 35747907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.
    Ribbing Wilén H; Blom J
    J Med Screen; 2024 Mar; 31(1):8-14. PubMed ID: 37455444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
    Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
    Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.